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COSTS TO TREAT COMMUNITY-ACQUIRED PNEUMONIA EPISODES IN 
US ADULTS AGED 50 YEARS AND OLDER BY AGE AND RISK
Sato R1, Strutton D1, Phillips B2, Grifﬁths S2
1Pﬁzer Inc., Collegeville, PA, USA, 2Ingenix Consulting, Eden Prairie, MN, USA
OBJECTIVES: This retrospective study assessed the costs to treat community-acquired 
pneumonia (CAP) episodes by risk, age, and hospitalization in US adults aged ≥50. 
METHODS: A multi-payer administrative claims database containing over 2 million 
lives aged ≥50 (800,000+ for aged ≥65) was used to identify CAP episodes between 
July 2006 and June 2007. An episode of pneumonia was deﬁned as the period between 
the ﬁrst and last pneumonia ICD-9 code with a chest x-ray claim. Episodes were also 
required to have a pre-post episode period free of pneumonia claims of at least 90 
days. Patients who were hospitalized or institutionalized in the 2 weeks prior to the 
start of the episode were excluded. Episode costs included all-cause medical and 
pharmacy costs. Results were stratiﬁed by age, risk (high: immunocompromised; 
moderate: immunocompetent with chronic medical condition; low: immunocompetent 
without chronic medical condition), and whether or not an episode included hospi-
talization. RESULTS: There were 21,086 CAP episodes among individuals aged ≥50 
with 29% resulting in hospitalization. Among those who were hospitalized, 48%, 
37%, and 15% were from the low, moderate, and high risk groups, respectively. The 
mean cost of a hospitalized CAP episode for the low, moderate, and high risk groups 
was $14,233, $19,470, and $ 27,032, respectively. For ages 50–64 years old, the mean 
cost of a hospitalized episode was $16,606 compared with $18,493 for age ≥65 years 
old. Costs of outpatient CAP episodes were substantially lower with a mean of $1047, 
$1241, and $2055 for low, moderate, and high risk groups, respectively. CONCLU-
SIONS: The cost to treat CAP which requires hospitalization is high regardless of risk 
category or age. Almost half of the hospitalized CAP patients do not appear to have 
traditional risk factors for pneumonia suggesting the need for better treatment and 
prevention strategies.
PRS18
ASSESSMENT OF THE CLINICAL AND ECONOMIC IMPACT OF AIR 
LEAKS DURING POST-OPERATIVE PULMONARY SURGERY
Nagel MP1, Gemmen E2, Smith BF3, Doyle J4, Garvert W2
1Neomend, Inc., Irvine, CA, USA, 2Quintiles, Falls Church, VA, USA, 3Quintiles Consulting, 
Hawthorne, NY, USA, 4Quintiles Global Consulting, Hawthorne, NY, USA
OBJECTIVES: Estimate the clinical and economic impact to U.S. hospitals of air leaks 
during post-operative pulmonary surgery. METHODS: Analysis of the 2006 Nation-
wide Inpatient Sample (NIS) hospital database. ICD-9 diagnosis and procedure codes 
were identiﬁed by expert medical opinion and a certiﬁed coder. For all stays with pul-
monary surgery, length of stay (LOS), total charges, and in-hospital mortality rates 
were compared between those stays including an air leak vs. those stays without an air 
leak. Unadjusted results were calculated using descriptive statistics (mean, median, 
frequencies, etc.) Adjusted results were calculated using multivariate regression analysis 
while controlling for age and gender. RESULTS: There were a total of 77,117 hospital 
inpatient stays with pulmonary surgery in 2006, 11,774 (15.3%) of which included air 
leak and 65,342 (84.7%) of which did not. Patients with pulmonary surgery stays 
including air leak were older than those patients without air leak (mean age = 61.5 yrs 
vs. 60.2 yrs; p = 0.0002), had a longer LOS on average (10.9 days vs. 7.4 days; p < 
0.0001), had more total charges ($67,554 vs. $52,550; p < 0.0001) and were more 
likely to die during their stay (2.87% vs. 2.25%; p = 0.0578). After adjusting for dif-
ferences in age and gender between the two groups, the incremental LOS, total charges 
and absolute risk of in-hospital mortality due to the presence of air leak is 3.54 days, 
$14,926 and +12.20%, respectively. The total nationwide additional economic impact 
of having an air leak after pulmonary surgery, estimated by applying patient level 
adjusted charges to the incidence of air leak, is $175.7 million. CONCLUSIONS: The 
clinical and economic impact to U.S. hospitals of air leaks during or following major 
pulmonary surgery is signiﬁcant. The reduction or elimination of these air leaks could 
save considerable hospital resources, payer dollars and patient lives.
PRS20
THE ECONOMIC BURDEN OF CHRONIC DISEASES IN ADULT US 
WORKERS IN TERMS OF MEDICAL EXPENDITURE AND LOST 
PRODUCTIVITY COSTS
Kwon JW1, Choi IS1, Qureshi Z1, Suh K2, McGuire M1, Kim CM3
1Rutgers University School of Pharmacy, Piscataway, NJ, USA, 2Rutgers University, East 
Brunswick, NJ, USA, 3Catholic University School of Medicine, Seoul, South Korea
OBJECTIVES: To estimate annual medical expenditure (ME) and lost productivity 
cost (PC) attributable to chronic diseases in working U.S. adults. METHODS: A 
cross-sectional design, using the 2003–2006 Medical Expenditure Panel Survey data 
was employed. We identiﬁed working adults who were 18–64 years old and classiﬁed 
them as having chronic diseases (arthritis, asthma, hypertension, hypercholesterolemia, 
or diabetes) or not. We excluded patients with malignancy, kidney dialysis, immuno-
deﬁciency, pregnancy, or BMI < 18.5. MEs were estimated using a generalized linear 
model with log link function and gamma distribution. PC was calculated based on 
missed working days due to illness and average hourly wage, using a two-part model. 
Costs attributable to chronic diseases were estimated by differences between actual 
and expected cost in patients with chronic diseases, using a distribution of covariates 
obtained from all patients. Treatment costs were converted to 2008 U.S. dollars using 
price indices. RESULTS: Among the identiﬁed 54,843 working adults, a third (34%) 
had at least one of ﬁve chronic diseases. Patients with two or ≥ three chronic diseases 
accounted for 8.5% and 3.7%, respectively. The average ME in patients with chronic 
diseases was signiﬁcantly higher than individuals without those diseases ($2997; 
95%CI = $2865–$3129 vs. $1021; 95%CI = $911–$1130). The average PC in these 
patients showed a similar trend ($481; 95%CI = $455–$507 vs. $236; 95%CI = 
$219–$253). Excess ME attributable to chronic diseases were estimated at $1605 
(95%CI:$1501–$1710) and excess PC at $173 (95%CI $172–$ 174). ME and PC 
increased with an increase in concurrent chronic diseases, respectively. Among the 
chronic diseases, arthritis and diabetes were the largest contributors to additional 
economic burden. CONCLUSIONS: The presence of chronic diseases in working 
patients resulted in signiﬁcantly higher ME and PC. The results highlight the additional 
economic burden attributable to chronic diseases in the working population and the 
need to allocate resources toward better management strategies for these diseases.
PRS21
ANALYSIS OF CLINICAL EFFICACY AND DIRECT COSTS OF THE 
SPECIFIC IMMUNOTHERAPY IN POLAND–A THREE-YEAR 
RETROSPECTIVE STUDY
Jahnz-Roozyk KM, Targowski T, Przekora P
Military Institute of the Health Service, Warsaw, Poland
OBJECTIVES: The aim of the study was 1) To evaluate the clinical efﬁcacy of speciﬁc 
allergen immunotherapy (SIT), and 2) To assess which patients have most beneﬁts 
from SIT METHODS: The investigations were carried out on the group of 120 
patients (37 children, and 83 adults). The effects of SIT (subcutaneous, perennial, 
Allergopharma, Germany) were evaluated through the means of the rate of reduction 
of allergic symptoms and utilization of anti-allergic symptomatic drugs. The cost of 
drugs was based on the catalogue price lists. Linear regression models have been used 
for assessment of relationship between reduction of intensity of allergic symptoms and 
savings on symptomatic drugs. RESULTS: After 3 years of the SIT mean percentage 
of reduction of allergic symptoms and utilization of symptomatic drugs was about 
80%. Mean savings on symptomatic treatment (PLN/EUR) {1EUR = 4PLN in 2009} 
were 664.5/166,1 (95%CI: 517.4/129.4−811.7/202.9) from social perspective and 
274.3/68.5 (95%CI: 227.4/56.8−321.2/80.3) from the patient’s perspective. The 
largest clinical improvement of allergic symptoms was observed in patients with 
combination of seasonal allergy (r = 0.25; p = 0.01), allergic rhinitis (r = 0.21; p = 
0.02) and bronchial asthma (r = 0.34; p = 0.0002). Presence of bronchial asthma was 
also signiﬁcantly related to the volume of savings on anti-allergic symptomatic treat-
ment from the social (r = 0.37, p = 0.0002) and patient’s (r = 0, 31; p = 0.003) per-
spectives. CONCLUSIONS: SIT signiﬁcantly decreases symptoms and anti-allergic 
drug intake. From social and patient’s perspective, SIT in patients with asthma essen-
tially reduces costs of symptom-relieving drugs. It can be a premise to consider to 
increase a level of reimbursement of SIT in this group of patients in Poland.
PRS22
COST-BENEFIT ANALYSIS OF VARENICLINE VS. EXISTING SMOKING 
CESSATION STRATEGIES IN PREGNANT WOMEN
Barnard M, Price J
The University of Mississippi, University, MS, USA
OBJECTIVES: Despite well documented harm to both the mother and the fetus, 
maternal smoking during pregnancy continues to hover above 15%. While pharma-
ceutical interventions have been shown to be cost-effective in the general population, 
current treatment options are poorly understood, insufﬁciently utilized and insufﬁ-
ciently effective in pregnant women. No data regarding safety or efﬁcacy of varenicline 
has been reported for this population. To determine if clinical study of varenicline for 
pregnant smokers is warranted, a cost-beneﬁt analysis of varenicline compared to 
existing treatment modalities will determine if there is likely any cost-beneﬁt associated 
with varenicline use in this population. METHODS: A decision analysis model was 
developed to evaluate from the payer’s perspective the optimal treatment from the 
standpoint of cost versus beneﬁt of potential treatment with varenicline compared to 
other smoking cessation treatment options in pregnant smokers. Outcomes included 
smoking cessation rates, cost of maternal and infant outcomes associated with 
smoking, and treatment costs. A sensitivity analysis was performed to determine the 
effects of variations in the success of treatment with varenicline. RESULTS: The 
analysis showed that buproprion is more cost-beneﬁcial than the other treatments, 
with a net beneﬁt of $1086 per pregnant smoker who attempts to quit, compared with 
$316 for usual care, $550 for motivational interviewing, $830 for NRT, and $938 
for varenicline. Sensitivity analyses indicate that at a 25% cessation rate, varenicline 
becomes the most cost-beneﬁcial treatment option. CONCLUSIONS: From a payer’s 
perspective and current knowledge of cessation rates with pregnant smokers, bupro-
prion is more cost-beneﬁcial smoking cessation intervention in pregnant women than 
existing treatment options. If pregnant smokers are more successful than non-pregnant 
smokers at quitting on varenicline, as they are with the other cessation treatments, it 
is likely that varenicline is the most cost-beneﬁcial treatment and may warrant addi-
tional study in this population.
PRS23
THE POTENTIAL COST IMPACT OF USING A PEG HYDROGEL 
SEALANT TO PREVENT AIR LEAKS AFTER LUNG RESECTION SURGERY 
IN THE UNITED KINGDOM
Minshall ME1, Larkin MJ2, Ott M3
1Covidien, North Haven, CT, USA, 2PRMA Consulting, Fleet, UK, 3Covidien, Zurich, 
Switzerland
OBJECTIVES: Persistent air leaks after lung resection surgery often lead to increased 
complications including longer length of hospital stay and subsequent treatment costs. 
A200 Abstracts
A PEG hydrogel sealant (PleuraSealTM) is used as an adjunct to standard closure of 
pleural air leaks during lung resection surgery and has demonstrated shorter hospi-
talizations (1.7 days fewer) and more rapid removal of chest tubes in clinical studies 
when compared with standard of care (e.g. staples and sutures alone). Our study was 
designed to estimate the potential cost offsets for using PleuraSealTM compared with 
standard of care in 100 hypothetical patients from a UK hospital who had an air leak 
after lung resection surgery using the cost offset from shorter hospital stays balanced 
against the cost for PleuraSealTM. METHODS: We assumed the cost for PleuraSealTM 
to be £360 per treatment applied to all 100 hypothetical patients compared with no 
added cost for standard of care. We then balanced the added cost for PleuraSealTM 
with the reduction in number of hospital days and subsequent costs compared with 
standard of care (£280/day @1.7 days fewer per patient) and calculated the potential 
cost offsets for PleuraSealTM. RESULTS: A hospital with 100 lung resection surgery 
patients with air leaks can expect to save £11,588, or approximately £17 per patient 
when compared to standard of care as patients who had air leaks stayed in hospital 
an average of 1.7 days longer than those without air leaks. CONCLUSIONS: The cost 
for PleuraSealTM is completely offset by the shorter length of hospital stay compared 
with standard of care. PleuraSealTM is a compelling option for hospitals who perform 
lung resection surgeries as the cost of the treatment is completely offset by the reduc-
tion in air leaks and subsequent hospital stay.
PRS25
ALBUTEROL AND LEVALBUTEROL USE AND SPENDING IN MEDICARE 
BENEFICIARIES WITH COPD
Puig A, McElligott S, Bergquist H, Doshi J
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: There is inconclusive evidence on the advantages of branded levalb-
uterol over generic albuterol. This study is the ﬁrst to examine the use and spending of 
these two short-acting beta agonists in a nationally representative sample of Medicare 
patients with COPD enrolled in Medicare Part D. The study also examines patient 
characteristics associated with levalbuterol use and compares the use of other Medicare 
Parts B and D covered COPD medications among albuterol and levalbuterol users. 
METHODS: Data were obtained from the 2005–2006 5% Medicare ﬁles linked to the 
2006 Medicare Part D ﬁles. The sample consisted of all fee-for-service beneﬁciaries with 
COPD enrolled in stand-alone Part D plans in 2006. Patient characteristics and other 
COPD medication use were compared across albuterol-only users, levalbuterol-only 
users, and users of both medications. Multinomial logistic regressions identiﬁed the 
independent factors associated with levalbuterol use. RESULTS: There were 5.5 times 
more albuterol users than levalbuterol users; yet total spending on levalbuterol was 
$169 million whereas on albuterol was $50 million in 2006. Levalbuterol-only users 
were more likely to be older, sicker, and reside in the South than albuterol-only users. 
Part B covered nebulizer formulations were more frequently used among levalbuterol-
only users whereas albuterol-only users were more likely to use inhalers under Part D. 
CONCLUSIONS: Our ﬁndings on the striking differences between levalbuterol and 
albuterol users in terms of spending, patient characteristics, geographic region, and 
drug formulation/device type call for further investigations into these issues as well as 
comparative effectiveness and cost-effectiveness studies of these agents.
PRS26
COST-UTILITY ANALYSIS OF TIOTROPIUM, MEDICINE FOR CHRONIC 
OBSTRACTIVE PULMONARY DISEASES (COPD) , IN JAPAN
Igarashi A1, Kato Y1, Makita H2, Fukuda T1, Nishimura M2, Tsutani K1
1Tokyo University, Tokyo, Japan, 2Hokkaido University School of Medicine, Sapporo, Japan
OBJECTIVES: To assess cost-effectiveness of tiotropium (Spiriva®), long-acting anti-
cholinergic agent for Chronic Obstructive Pulmonary Diseases (COPD), and ipratro-
pium in Japan. METHODS: A Markov model was constructed to analyze costs and 
Quality-Adjusted Life Years (QALYs) from the health care payers’perspective. Prior to 
construct the model, we assessed utility scores (disease-speciﬁc SGRQ scores and 
EQ-5D scores) and out-patient medicinal costs among COPD patients visiting Hok-
kaido University Hospital, classiﬁed by COPD severity. Medical costs other than 
medicinal costs (diagnosis, hospitalization, exacerbation, etc) were calculated from 
health insurance claim data in Hokkaido University Hospital. We captured costs and 
outcomes for 5 years. In the Markov model, 1 month was set as one cycle. Both costs 
and utility were discounted at 3% annually. We set the numbers of exacerbations and 
QALYs as outcomes. RESULTS: Both of SGRQ scores and EQ-5D scores were signiﬁ-
cantly inﬂuenced by COPD severity. Average EQ-5D scores for severe/very severe and 
moderate patients were 0.68,and 0.87, respectively. Average SGRQ scores for severe/
very severe and moderate patients were 26.1 and 46.1, respectively. COPD severity also 
signiﬁcantly inﬂuenced out-patient medicinal costs. Per diem out-patient medicinal 
costs of severe/very severe and moderate patients were JPY338 and 135, respectively 
(USD1 = JPY92) . As the results of Markov-model analysis, tiotropium would save 
JPY966,000 or USD10,500 (JPY2,604,000 vs. JPY3,570,000) , reduce the numbers of 
exacerbations (0.46 vs. 0.99) and increase 0.258QALY (3.300 vs. 3.042), compared to 
ipratropium.Various sensitivity analysis, both one-way and probabilistic one, showed 
the robustness of the results. From the budget impact analysis, if whole 220,000 COPD 
patient (based on Patient Survey 2005), use tiotropium instead of ipratropium, we 
would save JPY215 bil or USD2.34bil. CONCLUSIONS: Spiriva® for COPD patients 
in Japan, is thought to be cost-effective and would save health care budget.
PRS27
COST-UTILITY ANALYSIS OF ANTI-SMOKING TREATMENTS
Brault C1, Rinfret S2, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Quebec Heart and Lung Institute, Quebec, 
QC, Canada
OBJECTIVES: Approximately 4.5 million Canadians, or 18.6% of the total popula-
tion, smoke. Although the prevalence of smoking has shown a signiﬁcantly decreasing 
trend, nicotine dependence remains a major public health issue. A number of phar-
macological treatments are available to help smokers quit such as nicotine replacement 
therapies, bupropion and varenicline. The objective of this study was to evaluate the 
incremental cost-utility ratio of pharmacological anti-smoking treatments. METHODS: 
A Markov model based on the Benesco Simulation model (the Beneﬁts of Smoking 
Cessation on Outcomes) was developed to determine the costs and QALYs associated 
with the nicotine replacement therapies, bupropion and varenicline. This cost-utility 
analysis was performed over a lifetime horizon and from a health care system perspec-
tive. The model considers the health status of smokers, recent non-smokers and long-
term non-smokers; the adverse health outcomes of smoking (asthma, chronic 
obstructive pulmonary disease [COPD], coronary heart disease, stroke and lung 
cancer); and deaths from all causes and from smoking. The model also considers 
smoking cessation probabilities associated with anti-smoking treatments, probabilities 
of resuming, probabilities of complications attributable to smoking, and probabilities 
of death. The costs considered are the costs of anti-smoking treatments according to 
recommended doses and amounts reimbursed by the Régie de l’assurance maladie du 
Québec. RESULTS: Nicotine patches, with higher costs and less QALYs, are domi-
nated by both bupropion and varenicline. Nicotine gum is also dominated by bupro-
pion. Varenicline is the most effective of the anti-smoking treatments studied, albeit 
more costly than nicotine gum and bupropion. The incremental cost-utility ratios for 
varenicline versus nicotine gum and bupropion are respectively $825 and $1,235 per 
QALY. CONCLUSIONS: Results show that varenicline is the most effective option 
of the currently available pharmacological anti-smoking treatments, with a very 
acceptable cost-utility ratio.
PRS28
COST-UTILITY ANALYSES OF DISEASE-MODIFYING THERAPIES FOR 
PATIENTS WITH RELAPSE-REMITTING MULTIPLE SCLEROSIS IN THE 
UNITED STATE
Yang M, Tseng WW, Sansgiry SS
University of Houston, Houston, TX, USA
OBJECTIVES: To assess cost effectiveness of Natalizumab, Glatiramer Acetate (GA) 
and Interferon-β in treating patients diagnosed with relapsing-remitting multiple scle-
rosis (RRMS) from a United States (US) patient’s perspective. METHODS: A 30-year 
Markov model was developed with patients transitioning through health states based 
on the Kurtzke Expanded Disability Status Scale (EDSS). Patient health status was 
deﬁned as mild, moderate, or severe when their EDSS score was 0.0–3.5, 4.0–6.0, 
6.5–9.5, respectively. The model was parameterized with data from an extensive lit-
erature review and was adjusted where necessary to 2008 values. Transition probabili-
ties included patients initial distribution based on EDSS score, relapse rate, mortality 
rate, and progression rate. The total cost included direct (inpatient and outpatient 
admissions, ofﬁce visits to physicians, examinations, medication, medical devices, 
alterations to the care, and informal care from family) and indirect costs (productivity 
losses, and early retirement). The utility considered was Quality Adjusted Life-Year 
(QALY). Sensitivity analyses were conducted on all the transition probabilities at a 
range of ± 25% to check the robustness of the result. RESULTS: Based on the result 
of the 30 year Markov Model, patients treated with Natalizumab spend $1,104,773 
to gain 10.47 QALYs, while patients treated with Interferon- β spend $880,199 to 
obtain 9.88 QALYs and for those patients treated with GA have to pay $907,854 to 
yield 7.07 QALYs, which means patients treated with Natalizumab, Interferon-β or 
GA have to spend $105,517, $89,088, $128,409 respectively to gain one QALY. The 
model suggests that Interferon-β is the most cost-effective DMT agent, with an ICER 
of $380,634 per QALY compared with Natalizumab. Compared with GA, the ICER 
for Interferon- β per QALY was $9,841. Sensitivity analysis showed that the results 
were robust to changes in all parameters. CONCLUSIONS: In our study, Interferon-β 
proved to be more cost effective than both Natalizumab and GA for RRMS patients.
PRS29
SMOKING AND WORKPLACE CONSEQUENCES: EVALUATION IN 
FRANCE
Dautzenberg B1, Osman J1, Pibourdin JM2, Charles T3
1OFT, PARIS, France, 2Pierre Fabre, Boulogne cedex, France, 3CREES PFSA, Boulogne, 
France
OBJECTIVES: Tobacco is the primary cause of preventable death in France (66,000 
deaths/Y). Places of work and business are no exception.The objective of this study is 
to gain a better understanding of smoking and its consequences at work, thereby per-
mitting new data to be obtained which will encourage businesses to take smoking into 
account. METHODS: In June 2009, the CSASantéInstitute composed a representative 
sample of the active French population according to the quota method. A total of 1950 
people were interviewed. RESULTS: Of the total active population, there is no signiﬁ-
cant difference according to business size relative to the prevalence of smokers. The 
relationship between smoking and the number of breaks is linear (1 break for 2.5 ciga-
rettes smoked/day). Smokers are subject to even more criticism (because of their break) 
by their colleagues and their hierarchy if they are heavy smokers. Smokers of more than 
1 pack a day tend to be accompanied for their breaks. Smokers have more disrupted 
